Truace
Subscribe

A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma

Background: Surgical resection is the standard treatment for stage I lung adenocarcinoma, in most cases without additional systemic adjuvant treatment. A substantial proportion of stage I cases recur, with a 5-year survival rate <50%. Clinical data suggest that adjuvant treatment, including immune checkpoint inhibitor therapy, may improve survival in such recurrent cases. Previously evaluated predictors, including the International Association for the Study of Lung Cancer (IASLC) grading system applied to histol…

By the Truvace desk2 min read1 sourcePeer-reviewedTRV-2026-1585· cite & verify
A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
United States Naval Medical Bulletin, Vol. 41, Nos. 1-6, 1943 by U.S. Navy. Bureau of Medicine and Surgery. Public domain

In brief

Researchers built PATH-ORACLE, a multimodal deep learning biomarker that adds routine histological sections, read by pretrained foundation models, to an existing validated transcriptomic risk score for stage I lung adenocarcinoma. It was tested in two independent cohorts and outperformed each of its component predictors on recurrence risk.

Better risk stratification matters because many stage I patients recur after surgery, yet adjuvant treatment is not routinely given. The tool is so far only prognostic, and the authors say extensive further validation is needed before it could guide who receives adjuvant therapy.

Main points

  1. PATH-ORACLE builds on the prospectively validated transcriptomic ORACLE score and adds histology analyzed by pretrained foundation models.
  2. The histology-only predictor outperformed automated IASLC grading and stayed prognostic after adjustment for tumor size, grade and T-stage.
  3. One-year recurrence AUC was 0.86 and 0.84 in the two independent validation cohorts.
  4. A single prespecified cut-off separated high-risk from low-risk groups.

The gain

Combining routine histology slides with a transcriptomic score predicted 1-year recurrence more accurately than either source alone, across two independent validation cohorts.

The rundown

Surgery is the standard treatment for stage I lung adenocarcinoma and usually involves no additional systemic adjuvant therapy. The source notes that a substantial share of cases recur, with 5-year survival below 50% in those cases, and that clinical data suggest adjuvant treatment such as immune checkpoint inhibitors may improve survival.

Prior predictors, including IASLC grading of histological sections and transcriptomic profiles, were described as not sufficiently accurate or consistent for risk stratification or treatment guidance. The authors hypothesized that these measurements carry complementary information that gains power when combined.

The authors envision eventual use to prioritize stage IB patients for adjuvant targeted therapy, chemotherapy or immune checkpoint inhibitor therapy, with or without liquid biopsy-based monitoring, but that would require converting it from a prognostic to a predictive biomarker.

Sources

  1. Peer-reviewedImmuno-Oncology and Technology2026-09-17

The debate